EDMONTON, Alberta, April 6 /PRNewswire-FirstCall/ -- Medical Services International Inc. (OTC:MSITF) is pleased to announce that the demand for its VScan Dengue Fever rapid test kit has increased dramatically. Currently the Company is shipping its Dengue Fever test kit into 6 different countries and has had requests for information from another 12 countries. With the start of the mosquito season in many tropical countries it appears that Dengue Fever is becoming prevalent throughout the Middle East, Malaysia, and Southeast Asia. Further based on testing done in the Caribbean last year, it appears that Dengue Fever is increasing there as well. Dengue Fever comes in 4 forms. In the mildest form it can incapacitate an individual for up to 6 months. In the worst form the individual dies within days through massive hemorrhaging. The only treatment is fluid replacement therapy which must be started immediately. Standard laboratories take a minimum of three (3) days to as long as twenty-one (21) days to complete the testing. Very few laboratories are even capable of doing the testing for Dengue Fever. The VScan Dengue Fever test kit gives results in less than 15 minutes and is accurate greater than 99% of the time. The key to controlling an outbreak of Dengue Fever is early diagnosis. The VScan Dengue Fever is an excellent tool to be used in this manner. Based on current orders, plus ongoing negotiations and the requests for information that the Company is receiving concerning the Dengue Fever test kits it is reasonable to anticipate that we will sell in excess of 400,000 Dengue Fever test kits this year which will generate gross revenue of approximately US $1,200,000. About VScan The VScan rapid test kit is a single use, disposable, accurate, cost effective, easy to use, test for the screening of HIV 1&2, Hepatitis B&C, Tuberculosis (TB), Dengue Fever, West Nile, Syphilis, Malaria, and Prostate Cancer. The kits cannot be sold in Canada. Medical Services International Inc trades in the United States on the NQB Pinksheets under the symbol "MSITF". For further information, please contact Robert Talbot at (780) 430 6363 or http://www.medicalservicesintl.com/ or http://www.minerva-biotech.com/ . NOTE: Certain statements in this press release are "forward-looking statements" within the meaning of the Private Securities Act of 1995. Such statements involve known and unknown risks, uncertainties and other factors that may cause results to differ materially. Such risks, uncertainties and other factors include but are not limited to new economic conditions, risk in product development, market acceptance of new products and continuing product demand, level of competition and other factors described in Company reports and other filings with regulatory bodies. DATASOURCE: Medical Services International Inc. CONTACT: Robert Talbot of Medical Services International Inc., +1-780-430-6363 Web site: http://www.medicalservicesintl.com/ http://www.minerva-biotech.com/

Copyright